Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.

Max J GordonMichael ChurnetskiHamood AlqahtaniXavier Issac RiveraAdam KittaiStephen M AmrockSpencer JamesSheila HoffSudhir MandaStephen E SpurgeonMichael ChoiJonathon B CohenDaniel PerskyAlexey V Danilov

Published in: Cancer (2018)

Comorbidities portend a poor prognosis among patients with CLL treated with ibrutinib. Prospective studies are needed to optimize the treatment of patients with CLL who have comorbidities. Cancer 2018. © 2018 American Cancer Society.

Keyphrases

chronic lymphocytic leukemia
poor prognosis
papillary thyroid
long non coding rna
squamous cell
childhood cancer
skeletal muscle